Effective January 4, 2022, Yael German resigned from the board of directors of NeuroSense Therapeutics Ltd. in connection with her appointment as the Israeli ambassador to France. The Board has appointed Dr. Revital Mandil-Levin as a new member of the Board to replace Ms. German effective upon Ms. German's resignation from the Board. Dr. Mandil-Levin will serve as a Class I director, and her term will expire at the annual general meeting of shareholders to be held in 2022.

Dr. Mandil-Levin has more than 15 years' experience in biotech startups and product development in the pharmaceutical industry. She is currently the CEO and founder of Nanocarry Therapeutics Ltd., a private company developing a proprietary platform technology for the delivery of biologics across the blood-brain barrier for CNS indications. From September 2019 to November 2020, she served as VP Corporate Development of Anima Biotech, a private company with a novel approach for the discovery of small molecules involved in mRNA translation, and from April 2018 to February 2019, she served as Chief Business Development Officer of CollPlant Ltd.